{
    "clinical_study": {
        "@rank": "110970", 
        "arm_group": {
            "arm_group_label": "IncobotulinumtoxinA", 
            "arm_group_type": "Experimental", 
            "description": "The total dose will depend on the extent of the area involved by pain.  The injections will be carried out through a 1cc syringe using a \u00bd to 1 inch needle intramuscularly or subcutaneously (or both). The number of injections will not exceed 5 sites."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to investigate the safety and effectiveness of\n      botulinum toxin A (Xeomin) \u00ae injections in patients who suffer from focal pain in areas of\n      radiation and/or surgery as a result of cancer treatment. Our hypothesis is that injection\n      of incobotulinum toxin A into an area of local pain, at or around the area of a\n      post-surgical/post radiation scar, relieves the focal cancer pain."
        }, 
        "brief_title": "IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "Please contact the PI for more detailed information."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects 18- 80 years, both sexes, all races and ethnic groups.\n\n          -  Diagnosis of post- surgical/post - radiation cancer pain.\n\n          -  Focal pain duration longer than 3 months\n\n          -  Pain of moderate to severe intensity ( mean VAS over the previous week >4 )\n\n          -  Subjects who are able to read, speak, and understand English.\n\n        Exclusion Criteria:\n\n          -  Existing significant acute medical condition (i.e. cardiovascular, endocrine,\n             hematologic, neoplastic, infectious, or autoimmune disorders).\n\n          -  Pregnancy or planned pregnancy (determined by urine pregnancy test). Women of\n             childbearing age should use a reliable mode of contraception during the study period\n             (abstinence, etc).\n\n          -  Active breast feeding.\n\n          -  Enrollment in any clinical trial (currently or within the past 3 months) in which\n             treatments are imposed by a protocol.\n\n          -  Any subject for whom botulinum toxin treatment would be contraindicated; known\n             allergy or sensitivity to medication.\n\n          -  Subjects who are younger than 18 years of age.\n\n          -  Neuromuscular-junction disorders.\n\n          -  Axis I diagnosis determined by a neurologist or psychiatrist.\n\n          -  Use of anesthetic medications within two weeks or corticosteroid injections within 4\n             weeks of enrollment.\n\n          -  Received botulinum toxin injections in the past 4 months.\n\n          -  Patients taking high doses of aminoglycosides  or other drugs affecting the function\n             of neuromuscular junction ( anticholinergic, muscle relaxants)\n\n          -  Patients who have unstable pain in/at sites other than areas of planned injection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931865", 
            "org_study_id": "1205010328"
        }, 
        "intervention": {
            "arm_group_label": "IncobotulinumtoxinA", 
            "description": "Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment.  The total dose will depend on the extent of the area involved by pain.   botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.", 
            "intervention_name": "IncobotulinumtoxinA", 
            "intervention_type": "Drug", 
            "other_name": "Xeomin"
        }, 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins, Type A"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cancer pain, radiation therapy, surgery", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "bahman.jabbari@yale.edu", 
                "last_name": "Bahman Jabbari, MD", 
                "phone": "203-499-9691"
            }, 
            "contact_backup": {
                "email": "diana.richardson@yale.edu", 
                "last_name": "Diana Richardson, MD", 
                "phone": "203-737-2464"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06510"
                }, 
                "name": "Yale Physician Building"
            }, 
            "investigator": [
                {
                    "last_name": "Duarte Machado, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Diana Richardson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bahman Jabbari, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation", 
        "other_outcome": {
            "description": "The Patient Global Impression of Change questionaire asks patient level of satisfaction with current treatment (from very unsatisfactory to very satisfactory).", 
            "measure": "Patient Global Impression of Change (PGIC)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "email": "bahman.jabbari@yale.edu", 
            "last_name": "Bahman Jabbari, MD", 
            "phone": "203-499-9691"
        }, 
        "overall_contact_backup": {
            "email": "diana.richardson@yale.edu", 
            "last_name": "Diana Richardson, MD", 
            "phone": "203-737-2464"
        }, 
        "overall_official": {
            "affiliation": "Yale School of Medicine", 
            "last_name": "Bahman Jabbari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "visual analogue scale (VAS), a line which represents the level of pain in 10cms and you will show where your pain is on this line (0 no pain, 10 worst pain).", 
            "measure": "visual analogue scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931865"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Bahman Jabbari", 
            "investigator_title": "Professor of Neurolog", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "quality of life scale consists of 10 questions regarding how pain affects your quality of life.", 
            "measure": "quality of life scale(QLS)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "Merz Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}